🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

After WHO loses its top donor in US, Novo Nordisk Foundation and China step up with large contributions fiercepharma.com/pharma/after-w…

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population fiercepharma.com/pharma/fda-adv…

AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception ranking fiercepharma.com/marketing/astr…

GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity fiercepharma.com/pharma/gsk-tar…

After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial fiercepharma.com/pharma/after-k…

Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms fiercepharma.com/pharma/except-…

CDC pulls COVID vaccine recommendation for pregnant women, healthy children: RFK Jr. fiercepharma.com/pharma/rfk-jr-…

AbbVie's Allergan Aesthetics unit plots 202 layoffs after recent sales slide fiercepharma.com/pharma/abbvies…

InflaRx drops rare skin disease study for COVID med vilobelimab after futility signal fiercepharma.com/pharma/inflarx…

Big Pharma likely to endure Trump's tariff, pricing pressures, but threats to generics persist: S&P fiercepharma.com/pharma/big-pha…

Drugmakers, trade groups and others voice concerns with pharma-specific tariffs fiercepharma.com/pharma/governm…

Alcon gains first FDA prescription drug nod since Novartis split fiercepharma.com/pharma/alcon-g…

This week on "The Top Line," the Fierce team breaks down Big Pharma Q1 earnings, discusses gene therapy highlights from the ASGCT conference and shares an ASCO meeting preview. omny.fm/shows/the-top-…

With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B fiercepharma.com/pharma/opella-…

Theravance hands off the last of its Trelegy royalties to GSK for $225M fiercepharma.com/pharma/therava…

Agenus transfers pair of CA production plants to Zydus as part of $141M partnership fiercepharma.com/manufacturing/…

ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear fiercepharma.com/pharma/jjs-ake…

ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation fiercepharma.com/pharma/sanofi-…

ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop fiercepharma.com/pharma/bristol…

Bayer gains key FDA expansion for fast-rising prostate cancer drug Nubeqa fiercepharma.com/pharma/bayer-g…